Endotronix CEO Harry Rowland, PhD, co-founded the heart sensor company 11 years ago and assumed the CEO role in 2012. Over that span, the company has raised more than $100 million from VCs, found regulatory success in Europe, and now is moving toward seeking approval in the US. What lessons has the first-time CEO learned running a start-up? How has Endotronix managed discouraging news in its space? And, in the past, how often has he asked himself, is this is going to work?
CEO & President
Dr. Rowland has led the company’s operations, strategy, and technology development since inception. He received his PhD in mechanical engineering from the Georgia Institute of Technology as well as a BS in mechanical engineering and MA in economics from the University of California, Santa Barbara. Dr. Rowland’s professional interests are at the intersection of transformative technologies and emerging business opportunities. He has been active in research and development of micro and nanotechnology fabrication methods for 15 years, including invited research at Sandia National Laboratories, New Mexico and Trinity College, Ireland. Dr. Rowland has authored or presented over 15 conference and journal papers in internationally recognized peer-reviewed publications such as Science and Nano, with his work referenced in more than 300 scholarly articles. He is an inventor on 10 issued patents and several pending applications.
Meet Our Host
A follower and fan of medtech for nearly two decades, Tom Salemi is the former bureau chief, venture capital, at Elsevier Business Intelligence, where he oversaw coverage of venture investments in medtech.